Vicente Anido Jr
CIK 1207633 · Chief Executive Officer · last filed 2021-02-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AERI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CORONA DEL MAR, CA 92625
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Chief Executive Officer | 243,896 | $15.25 | $3.72M | -$11.66M | 22 | 2021-02-25 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | 4,403 | — | — | $0 | 6 | 2016-05-13 |
| QLTI | Director | — | $28.01 | — | $0 | 2 | 2013-07-17 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | President & CEO | 500,659 | — | — | $315.1K | 23 | 2012-05-10 |
| AHG | Director | 5,333 | $1.35 | $7.2K | $0 | 1 | 2007-05-07 |
Recent Filings · Page 4 of 6
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-06-15 | — | Mixed | −537,116 | -$6.06M | |
| 2012-05-10 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Mixed | +52,029 | -$6 | EDGAR |
| 2012-02-09 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −6,665 | -$54.4K | EDGAR |
| 2012-02-06 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −7,024 | -$57.6K | EDGAR |
| 2011-12-02 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Grant (A) | +89,336 | $89 | EDGAR |
| 2011-02-10 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −3,332 | -$24.9K | EDGAR |
| 2011-02-09 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Grant (A) | +36,350 | $36 | EDGAR |
| 2011-02-07 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −5,627 | -$34.6K | EDGAR |
| 2011-02-07 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −3,332 | -$20.7K | EDGAR |
| 2010-02-18 | ISTA PHARMACEUTICALS INC (ISTA) Delisted | Disp (D) | −1,705 | -$6.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.